← Back to Screener
Revelation Biosciences, Inc. Common Stock (REVB)
Price$1.20
Favorite Metrics
Price vs S&P 500 (26W)-82.56%
Price vs S&P 500 (4W)-2.54%
Market Capitalization$4.69M
All Metrics
Book Value / Share (Quarterly)$5.59
P/TBV (Annual)4.01x
Indicated Dividend (Annual)$0.00
Cash Flow / Share (Quarterly)$-5.22
Price vs S&P 500 (YTD)-63.27%
EPS (TTM)$-42.04
10-Day Avg Trading Volume0.07M
EPS Excl Extra (TTM)$-42.04
EPS (Annual)$-14.36
ROI (Annual)-100.59%
Cash / Share (Quarterly)$6.76
ROA (Last FY)-76.96%
EBITD / Share (TTM)$-14.35
ROE (5Y Avg)-305.08%
Cash Flow / Share (Annual)$-5.22
P/B Ratio0.53x
P/B Ratio (Quarterly)0.53x
Net Income / Employee (Annual)$-1
ROA (TTM)-105.47%
EV / EBITDA (TTM)-6.68x
EPS Incl Extra (Annual)$-14.36
Current Ratio (Annual)5.41x
Quick Ratio (Quarterly)5.38x
3-Month Avg Trading Volume0.46M
52-Week Price Return-96.98%
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$1.40
52-Week High$44.16
EPS Excl Extra (Annual)$-14.36
26-Week Price Return-78.57%
Quick Ratio (Annual)5.38x
13-Week Price Return-65.00%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)5.41x
Enterprise Value$-6.013
Revenue / Employee (Annual)$0
Cash / Share (Annual)$6.76
3-Month Return Std Dev89.75%
Net Income / Employee (TTM)$-1
ROE (Last FY)-100.59%
EPS Basic Excl Extra (Annual)$-14.36
EV / Free Cash Flow (TTM)-10.86x
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$-42.04
ROI (TTM)-134.19%
Revenue / Share (Annual)$0.00
Tangible BV / Share (Annual)$1.54
Price vs S&P 500 (52W)-126.81%
Year-to-Date Return-60.63%
5-Day Price Return2.44%
EPS Normalized (Annual)$-14.36
ROA (5Y Avg)-217.77%
Month-to-Date Return5.00%
Cash Flow / Share (TTM)$0.23
EBITD / Share (Annual)$-14.31
ROI (5Y Avg)-305.08%
EPS Basic Excl Extra (TTM)$-42.04
P/TBV (Quarterly)0.48x
P/B Ratio (Annual)0.53x
Book Value / Share (Annual)$5.59
Price vs S&P 500 (13W)-65.69%
Beta-0.12x
Revenue / Share (TTM)$0.00
ROE (TTM)-134.19%
52-Week Low$1.06
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
4.14
4.14
4.14
4.14
Industry Peers — Pharmaceuticals(309)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
REVBRevelation Biosciences, Inc. Common Stock | — | — | — | — | $1.20 |
LLYEli Lilly & Co. | 13.08x | 44.70% | 83.04% | 27.59% | $903.99 |
JNJJohnson & Johnson | 5.94x | 7.87% | 67.95% | 14.90% | $234.54 |
ABBVABBVIE INC. | 6.04x | 8.57% | 71.62% | -2.88% | $208.99 |
MRKMerck & Co., Inc. | 4.41x | 1.31% | 78.55% | 21.23% | $115.46 |
AZNAstraZeneca PLC | 5.28x | 8.63% | 81.31% | 21.88% | $200.47 |
NVSNovartis AG | 4.98x | 8.91% | 75.82% | 15.26% | $149.73 |
NVONovo-Nordisk A/S | 3.62x | 6.43% | 80.98% | 20.66% | $40.93 |
ABTAbbott Laboratories | 3.66x | 6.59% | 56.50% | 8.20% | $95.47 |
PFEPfizer Inc. | 2.47x | -1.64% | 75.81% | -3.51% | $27.22 |
BMYBristol-Myers Squibb Co. | 2.47x | -0.22% | 72.63% | — | $58.96 |
About
Revelation Biosciences is a clinical-stage biotech company developing immunology-based treatments using Gemini, a proprietary TLR4 agonist designed to modulate inflammatory responses for therapeutic benefit. The company's pipeline includes three Gemini-based programs: Gemini-SSI for surgical site infection prevention, Gemini-AKI for acute kidney injury prevention, and Gemini-CKD for chronic kidney disease treatment.